MICHAEL ANTHONY NASIAK, M.D.
Osteopathic Medicine at Charleston Blvd, Las Vegas, NV
License number
Nevada 8337
Category
Osteopathic Medicine
Type
Internal Medicine
Address
Address
1707 W Charleston Blvd, Las Vegas, NV 89102
Phone
(702) 671-5060
(702) 671-2376 (Fax)
(702) 564-2453
(702) 527-5353 (Fax)
(702) 671-2376 (Fax)
(702) 564-2453
(702) 527-5353 (Fax)
Professional information
Michael Anthony Nasiak, Las Vegas NV
Specialties:
Internist
Address:
1707 W Charleston Blvd, Las Vegas, NV 89102
2040 W Charleston Blvd, Las Vegas, NV 89102
2040 W Charleston Blvd, Las Vegas, NV 89102
Education:
State University of New York, School of Medicine and Biomedical Sciences (Buffalo) - Doctor of Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine
Dr. Michael A Nasiak - MD (Doctor of Medicine)
Specialties:
Internal Medicine
Certifications:
Internal Medicine, 2008
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
1707 W Charleston Blvd STE 230, Las Vegas 89102
1707 W Charleston Blvd STE 230, Las Vegas 89102
1707 W Charleston Blvd STE 230, Las Vegas 89102
Education:
Medical School
University At Buffalo State University Of New York School Of Medicine
Graduated: 1994
Buffalo General Hospital
Graduated: 1995
Graduated: 1997
University At Buffalo State University Of New York School Of Medicine
Graduated: 1994
Buffalo General Hospital
Graduated: 1995
Graduated: 1997
Use Of A Synthetic Alpha-Melanocyte Stimulating Hormone Agonist To Decrease Steroid Induced Weight Gain
US Patent:
2005010, May 12, 2005
Filed:
May 6, 2004
Appl. No.:
10/841961
Inventors:
David Rosenstein - Las Vegas NV, US
Michael Nasiak - Las Vegas NV, US
Michael Nasiak - Las Vegas NV, US
International Classification:
A61K038/22
US Classification:
514012000
Abstract:
People who are on chronic steroids are known to have depressed levels of ACTH and thus should also have decreased levels of α-MSH. Recent data show that people with altered Melanocortin-4 (MC4) receptors (receptor for α-MSH) have strongly associated rates (100%) of Binge Eating Disorder diagnosable of DSM IV criteria. All patients who are on steroids and have low levels of ACTH, and thus low levels of α-MSH, could appear phenotypically identical to those with altered Melanocortin-4 receptors (MC4R). Patients with iatrogenically induced α-MSH deficiencies (including patients on chronic steroid therapy) could be expected to respond to exogenous α-MSH or MC4R agonist supplementation. Exogenous α-MSH or MC4R agonist treatment should also decrease serum leptin levels; therefore, the present invention provides a method of decreasing steroid induced weight gain by employing α-MSH agonists.